Literature DB >> 31780856

Cracking KRAS.

Asher Mullard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31780856     DOI： 10.1038/d41573-019-00195-5

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  29 in total

1.  Differential Peptidoglycan Recognition Assay Using Varied Surface Presentations.

Authors:  Elizabeth A D'Ambrosio; Klare L Bersch; Mackenzie L Lauro; Catherine L Grimes
Journal:  J Am Chem Soc       Date:  2020-06-16       Impact factor: 15.419

Review 2.  Inhibition of Nonfunctional Ras.

Authors:  Ruth Nussinov; Hyunbum Jang; Attila Gursoy; Ozlem Keskin; Vadim Gaponenko
Journal:  Cell Chem Biol       Date:  2021-01-12       Impact factor: 8.116

Review 3.  [Medicinal treatment of pancreatic cancer : Still a domain of chemotherapy?]

Authors:  Georg Feldmann
Journal:  Internist (Berl)       Date:  2020-02       Impact factor: 0.743

4.  BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.

Authors:  Marco H Hofmann; Michael Gmachl; Juergen Ramharter; Fabio Savarese; Daniel Gerlach; Joseph R Marszalek; Michael P Sanderson; Dirk Kessler; Francesca Trapani; Heribert Arnhof; Klaus Rumpel; Dana-Adriana Botesteanu; Peter Ettmayer; Thomas Gerstberger; Christiane Kofink; Tobias Wunberg; Andreas Zoephel; Szu-Chin Fu; Jessica L Teh; Jark Böttcher; Nikolai Pototschnig; Franziska Schachinger; Katharina Schipany; Simone Lieb; Christopher P Vellano; Jonathan C O'Connell; Rachel L Mendes; Jurgen Moll; Mark Petronczki; Timothy P Heffernan; Mark Pearson; Darryl B McConnell; Norbert Kraut
Journal:  Cancer Discov       Date:  2020-08-19       Impact factor: 39.397

Review 5.  Precision Therapy of Pancreatic Cancer: From Bench to Bedside.

Authors:  Katrin Jana Ciecielski; Alexandra Berninger; Hana Algül
Journal:  Visc Med       Date:  2020-10-06

6.  Malfeasance of KRAS mutations in carcinogenesis.

Authors:  Rupal Tripathi; Shrinidhi Nathany; Anurag Mehta; Ullas Batra; Sakshi Mattoo; Mansi Sharma
Journal:  Clin Exp Med       Date:  2021-03-12       Impact factor: 3.984

7.  ERK Inhibition Improves Anti-PD-L1 Immune Checkpoint Blockade in Preclinical Pancreatic Ductal Adenocarcinoma.

Authors:  Kelly E Henry; Kyeara N Mack; Veronica L Nagle; Mike Cornejo; Adam O Michel; Ian L Fox; Maria Davydova; Thomas R Dilling; Nagavarakishore Pillarsetty; Jason S Lewis
Journal:  Mol Cancer Ther       Date:  2021-08-04       Impact factor: 6.261

8.  Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting.

Authors:  Adham S Bear; Tatiana Blanchard; Joseph Cesare; Michael J Ford; Lee P Richman; Chong Xu; Miren L Baroja; Sarah McCuaig; Christina Costeas; Khatuna Gabunia; John Scholler; Avery D Posey; Mark H O'Hara; Anze Smole; Daniel J Powell; Benjamin A Garcia; Robert H Vonderheide; Gerald P Linette; Beatriz M Carreno
Journal:  Nat Commun       Date:  2021-07-16       Impact factor: 17.694

9.  Genetic and pharmacological interrogation of cancer vulnerability using a multiplexed cell line screening platform.

Authors:  Yifeng Xia; Xiaodong Ji; In Sock Jang; Christine Surka; Christy Hsu; Kai Wang; Mark Rolfe; Neil Bence; Gang Lu
Journal:  Commun Biol       Date:  2021-07-02

10.  Virtual clinical trial simulations for a novel KRASG12C inhibitor (ASP2453) in non-small cell lung cancer.

Authors:  Hiroyuki Sayama; Diana Marcantonio; Takeyuki Nagashima; Masashi Shimazaki; Tsuyoshi Minematsu; Joshua F Apgar; John M Burke; Lucia Wille; Yasuhisa Nagasaka; Daniel C Kirouac
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.